

10644775
T.S. 9/28/07

IN THE SPECIFICATION

Please amend the application as follows:

1. Please add the attached page of Sequence Listing as the last page of the application.

- T.S.
9/28/07
2. Page 59, line ¹²~~15~~, (Par. [0217] of the published application) please amend as follows:

[0217] Wounds were effected on the back of 8-10 week old C57BL mice by incision and were treated daily for 7 days with either vehicle (PBS) control or with 0.67 μ M insulin (HO/01; Humulin ~~Humulin~~, Eli Lilly, USA) combined with a PKC α inhibitor of SEQ ID NO:1 (HO/02; ~~PKC α~~ PKC α pseudosubstrate myristoylated ~~myristoylated~~; Calbiochem ~~Calbiochem~~, San Diego, Calif., USA). Seven days after wounding all mice were sacrificed and treated wounds were analyzed for wound closure, epidermal closure, dermal closure, and spatial differentiation of epidermal cells. Wound closure was determined by measuring the open wound area. Dermal closure of wounds was considered positive if both wound sides the dermis could be observed in a single field observed under a light microscope at x10 magnification. Epidermal closure of wounds was determined by staining wound sections with K14 antibody which highlighted the formation of basal cells at the wound gap. Spatial differentiation of epidermal cells was determined by staining wound sections with K1 antibody which highlighted newly formed epidermal cells.